© 2020 MJH Life Sciences and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Biomarker-Driven Lung Cancer
Pembrolizumab Deemed Active Treatment for Brain Metastasis in NSCLC
April 15, 2020
Brain metastasis responses were elicited from treatment with pembrolizumab in patients with non–small cell lung cancer, in a PD-L1–positive cohort of a phase II clinical trial conducted by researchers at Yale Cancer Center. According to a YCC press release, pembrolizumab prolonged overall survival with limited toxicity in these patients.
FDA Clears IND for Novel Immunotherapy in Solid Tumors
April 15, 2020
The FDA has provided clearance to an Investigational New Drug application for GT103 for the treatment of solid tumors. A phase I clinical trial will be initiated to evaluate this novel targeted immunotherapy in patients with refractory non–small cell lung cancer, announced Grid Therapeutics, LLC.
Frontline Tislelizumab Combination Significantly Improves PFS in Nonsquamous NSCLC
April 14, 2020
The combination of tislelizumab, a PD-L1 antibody, pemetrexed and platinum-based chemotherapy achieved a statistically significant prolongation in progression-free survival compared with pemetrexed and platinum chemotherapy alone as first-line treatment of patients with nonsquamous non–small cell lung cancer, meeting the primary end point of a phase III BGB-A317-304 trial.
A 69-Year Old Man With Metastatic BRAF V600E-Mutated Metastatic NSCLC
April 14, 2020
A 69-Year Old Man With Metastatic BRAF V600E-Mutated Metastatic NSCLC
Options for Patients With Lung Cancer and Genetic Alterations
April 11, 2020
Luis E. Raez, MD, discusses targeted therapies for patients with lung cancer who have genetic alterations.
FDA Grants Priority Review to BLA for First-Line Nivolumab/Ipilimumab Plus Limited Chemo in NSCLC
April 08, 2020
The FDA has accepted the Biologics License Application for and granted Priority Review to the combination of nivolumab plus ipilimumab with limited chemotherapy as a first-line treatment of patients with metastatic or recurrent non–small cell lung cancer who have no EGFR or ALK genomic tumor aberrations, according to a press release from Bristol Myers Squibb. The Prescription Drug Free User Act target action date is set as August 6, 2020, and the combination was granted Fast Track designation.
Research on Molecular Mutations Guides Use of Targeted Therapies in Lung Cancer
April 08, 2020
In an interview with Targeted Oncology, James A. Reeves, MD, discussed how targeted therapies are being used presently in lung cancer and the potential of these agents in the future.
FDA Grants Pembrolizumab Priority Review for TMB-High Tumors
April 07, 2020
The FDA has accepted and granted a priority review to a supplemental Biologics License Application for pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic solid tumors with tissue tumor mutational burden-high who have progressed following prior treatment and who have no satisfactory alternative treatment options.
Evaluating the Role of Molecular Testing in Lung Cancer
April 03, 2020
Nathan A. Pennell, MD, PhD, discusses the role of molecular testing when treating and managing patients with lung cancer. He shares his advice on what to do for patients who need therapy immediately, as well.
Tedopi Vaccine Shows Positive Survival in HLA-A2-Positive Advanced NSCLC
April 02, 2020
The immunotherapeutic vaccine OSE-2101 demonstrated a favorable 12-month survival rate as second- or third-line treatment of patients with HLA-A2-positive advanced non–small cell lung cancer, meeting the primary end point of overall survival in the phase III Atalante 1 study, according to a press release from the drug developer, OSE Immunotherapeutics, Inc.